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Objective: Peroxisome proliferator-activated receptor B/D (PPARB/D) is the predominant PPAR subtype in cardiac cells and plays a
prominent role in the regulation of cardiac lipid metabolism. However, the role of PPARB/D activators in cardiac hypertrophy is not yet
known.
Methods and Results: In cultured neonatal rat cardiomyocytes, the selective PPARB/D activator L-165041 (10 Mmol/L) inhibited
phenylephrine (PE)-induced protein synthesis ([3H]leucine uptake), induction of the fetal-type gene atrial natriuretic factor (ANF) and cardiac
myocyte size. Induction of cardiac hypertrophy by PE stimulation also led to a reduction in the transcript levels of both muscle-type carnitine
palmitoyltransferase (50%, Pb0.05) and pyruvatedehydrogenase kinase 4 (30%, Pb0.05), and these changes were reversed in the presence of
the PPARh/y agonist L-165041. Stimulation of neonatal rat cardiomyocytes with PE and embryonic rat heart-derived H9c2 cells with
lipopolysaccharide (LPS) enhanced the expression of the nuclear factor (NF)-nB-target gene monocyte chemoattractant protein 1 (MCP-1).
The induction of MCP-1 was reduced in the presence of L-165041, suggesting that this compound prevented NF-nB activation.
Electrophoretic mobility shift assay (EMSA) revealed that L-165041 significantly decreased LPS-stimulated NF-nB binding activity in H9c2
myotubes. Finally, coimmunoprecipitation studies showed that L-165041 strongly enhanced the physical interaction between PPARh/y and
the p65 subunit of NF-nB, suggesting that increased association between these two proteins is the mechanism responsible for antagonizing
NF-nB activation by PPARh/y activators.
Conclusion: These results suggest that PPARB/D activation inhibits PE-induced cardiac hypertrophy and LPS-induced NF-KB activation.
D 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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Cardiac hypertrophy is a response of the heart to a wide
range of extrinsic stimuli, such as arterial hypertension,
valvular heart disease, myocardial infarction and hyper-0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2004.11.011
* Corresponding author. Tel.: +34 93 4024531; fax: +34 93 4035982.
E-mail address: mvazquezcarrera@ub.edu (M. Va´zquez-Carrera).trophic cardiomyopathy. Although this process is initially
compensatory for an increase workload, its prolongation
frequently results in congestive heart failure, arrhythmia
and sudden death [1,2]. Among the signal transduction
pathways involved in the hypertrophic growth of the
myocardium, the nuclear factor (NF)-nB signaling pathway
plays a pivotal role, since it has been shown that NF-nB
inhibition blocks or attenuates the hypertrophic response of
cultured cardiac myocytes [3–6]. In addition, cardiac
hypertrophy is associated with an increase in glucose
utilization and a decrease in fatty acid oxidation, which is65 (2005) 832–841ed by Elsevier B.V. All rights reserved.
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fatty acid oxidation enzymes cause childhood hypertrophic
cardiomyopathy [9], and perturbation of fatty acid oxida-
tion in animal models causes cardiac hypertrophy [10,11],
demonstrating that substrate utilization is important in the
pathogenesis of hypertrophy. Peroxisome proliferator-acti-
vated receptors (PPARs) are ligand-activated transcription
factors that regulate the expression of genes involved in
fatty acid uptake and oxidation, lipid metabolism and
inflammation [12]. The PPAR subfamily consists of three
subtypes, PPARa (NR1C1 according to the unified
nomenclature system for the nuclear receptor superfamily),
PPARh (also known as PPARy) (NR1C2) and PPARg
(NR1C3) [13]. PPARa is expressed primarily in tissues
that have a high level of fatty acid catabolism such as
liver, brown fat, kidney, heart and skeletal muscle [14].
PPARh/y is ubiquitously expressed, and PPARg has a
restricted pattern of expression, mainly in white and brown
adipose tissues, whereas other tissues such as skeletal
muscle and heart contain limited amounts. In order to be
transcriptionally active, PPARs need to heterodimerize
with the 9-cis retinoic acid receptor (RXR) (NR2B).
PPAR-RXR heterodimers binds to DNA specific sequences
called peroxisome proliferator-response elements (PPREs),
consisting of an imperfect direct repeat of the consensus
binding site for nuclear hormone receptors (AGGTCA)
separated by one nucleotide (DR-1). These sequences have
been characterized within the promoter regions of PPAR
target genes. However, the regulation of gene transcription
by PPARs extends beyond their ability to transactivate
specific target genes. PPARs are also able of regulating
gene expression independently of binding to DNA through
a mechanism termed receptor-dependent transrepression
[15]. One of these mechanisms involves a physical
interaction of PPARa with NF-nB, leading to suppression
activity of the latter [16].
It has been demonstrated that, of the three PPAR
subtypes, activation of both PPARa [17,18] and PPARg
[19,20] results in inhibition of cardiac hypertrophy.
However, the role of PPARh/y in the development of this
process is unknown. The recent availability of specific
synthetic ligands for PPARh/y, such as L-165041, now
makes possible to study the role of this nuclear receptor in
cardiac cells. Thus, recently, Gilde et al. [21], using neonatal
rat cardiomyocytes as well as the embryonic rat heart-
derived H9c2 cells, clearly demonstrated that PPARh/y is
the predominant PPAR subtype in cardiac cells and plays a
prominent role in the regulation of cardiac lipid metabolism,
suggesting that PPARh/y, similarly to PPARa and g, may
play an important role in cardiac disease.
In this study, we examined the role of PPARh/y activation
in phenylephrine (PE)-induced hypertrophy in neonatal rat
cardiac myocytes and in lipopolysaccharide (LPS)-estimu-
lated H9c2 myotubes. We found that activation of PPARh/y
inhibits PE-induced hypertrophy and LPS-induced NF-nB
activation.1. Methods
1.1. Materials
L-165041 was synthesized according to Berger et al.
[22]. [g-32P]dATP (3000 Ci/mmol) and [3H]leucine (50 Ci/
mmol) were purchased from Amersham Pharmacia Biotech
KK. Anti-atrial natriuretic factor (ANF) polyclonal anti-
serum was from Peninsula Laboratories and Alexa flouro
488 goat anti-rabbit and 568 goat anti-mouse antibodies
were from Molecular Probes. All other chemicals were
purchased from Sigma.
1.2. Cell culture
Neonatal rat ventricular myocytes from 1- to 2-day-old
Sprague–Dawley rats were prepared and cultured overnight
in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum as described previously [23].
The media was changed to serum-free DMEM supple-
mented with transferrin (10 Ag/mL), insulin (1 Ag/mL) and
bromodeoxyuridine (0.1 mmol/L) 24 h before treatments. In
this study, PE was used to stimulate neonatal rat cardio-
myocytes. Animal handling and disposal were performed in
accordance with NIH guidelines.
The embryonic rat-heart derived H9c2 cells (ATCC) were
maintained in growth medium composed of DMEM supple-
mented with 10% fetal bovine serum. H9c2 cells were plated
at a density of 5000 cells/cm2 and allowed to proliferate in
growth medium. Medium was changed every 3 days. To
induce differentiation of H9c2 myoblasts into myotubes,
growth medium was replaced with differentiation medium
(DMEM containing 2% horse serum) when cells had reached
near confluence. For mRNA analysis H9c2 cells were treated
with 10 Amol/L L-165041 and LPS (10 ng/mL) for 24 h.
1.3. Incorporation of [3H]leucine
To examine the effect of PE on protein synthesis, the
incorporation of [3H]leucine was measured essentially by
the method of Thaik et al. [24]. Cultured neonatal rat
ventricular myocytes were treated with PE in the presence or
in the absence of L-165041 and coincubated with [3H]leu-
cine (1 ACi/mL) for 24 h. The cells were washed with PBS
and then treated with 10% trichloroacetic acid at 4 8C for 30
min to precipitate the proteins. The precipitates were then
dissolved in NaOH (0.25 N). Aliquots were counted with
scintillation counter.
1.4. Immunocytochemistry
Neonatal rat ventricular myocytes were fixed in ice-cold
100% methanol for 10 min. Anti-a-actinin antibody and anti-
ANF polyclonal antiserum were added at dilutions 1:400 and
1:150, respectively, in PBS containing 1% BSA and
incubated for 1 h at room temperature. Secondary antibodies,
A. Planavila et al. / Cardiovascular Research 65 (2005) 832–841834Alexa flouro 488 goat anti-rabbit and Alexa flouro 568 goat
anti-mouse, were used at a dilution of 1:300 in PBS
containing 5% rat serum and incubated for 30 min at room
temperature. Immunofluorescence was visualized using a
confocal laser fluorescence microscope Olympus Fluoview
FV500. Photographic images were taken from five random
fields.Fig. 1. The PPARh/y activator L-165041 inhibits PE-induced cardiac hypertrophy
Amol/L PE in the presence or absence of 10 Amol/L L-165041 that was added 30
coincubating cardiac myocytes with 1.0 ACi/mL [3H]leucine for 24 h. Data are ex
the mRNA levels of ANF in PE-stimulated cardiomyocytes in the presence or abs
Effects of PE with and without L-165041 on cardiac myocyte ANF protein expres
performed using specific antibodies to a-actinin (upper panel, red color) and AN
similar results. ***Pb0.001 vs. control. #Pb0.05 vs. PE-stimulated cardiac myoc1.5. RNA preparation and analysis
Relative levels of specific mRNAs were assessed by
the reverse transcription–polymerase chain reaction (RT–
PCR) as previously described [25]. The sequences of the
sense and antisense primers used for amplification were:
ANF, 5V-TCCTCTTCCTGGCCTTTTGGC-3V and 5V-in neonatal rat cardiomyocytes. Cardiac myocytes were stimulated with 100
min before experiments. (A) [3H]leucine incorporation was determined by
pressed as meanFS.D. (n=6) of the treated-to-control ratio. (B) Analysis of
ence of 10 Amol/L L-165041. A representative autoradiogram is shown. (C)
sion and cardiac myocyte size. Double immunofluorescent microscopy was
F (lower panel, green color). Experiments were performed three times with
ytes.
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CTGCAGCCTGCCTGAATT-3V and 5V-ATGGTGTGAA-





monocyte chemoattractant protein 1 (MCP-1), 5V-GGGCCT-
GTTGTTCACAGTTGC-3 V and 5 V-GGGACACCT-
GCTGCTGGTGAT-3V; muscle-type carnitine palmitoyltrans-
ferase (M-CPT-I), 5V-TTCACTGTGACCCCAGACGGG-3V
and5V-AATGGACCAGCCCCATGGAGA;pyruvatedehydro-
genase kinase 4 (PDK-4), 5V-GAACACCCCTTCCGTC-
CAGCT-3V and 5V-TGTGCCATCGTAGGGACCACA-3V;
PPARg coactivator-1 (PGC-1), 5V-AGAAAGGGCCCGAG-
CAATCTG-3V and 5V-AGATGTGCCCCTGCCAGTCAC-3V;
p22, 5V-CCCCGGGGAAAGAGGAAAAAG-3V and 5V-Fig. 2. L-165041 prevents downregulation of the expression of several genes
cardiomyocytes. Analysis of the mRNA levels of M-CPT-I (A), PDK-4 (B), MCD
absence of 10 Amol/L L-165041. A representative autoradiogram and the quantific
as meanFS.D. of five different experiments. *Pb0.05 and **Pb0.01 vs. control.GGATGGCTGCCAGCAGGTAGA-3V; and APRT (adenosyl
phosphoribosyl transferase), 5V-GCCTCTTGGCCAGT-
CACCTGA-3Vand 5V-CCAGGCTCACACACTCCACCA-3V.
Amplification of each gene yielded a single band of the
expected size (ANF: 234 bp, gp91: 200 bp, iNOS: 198 bp,
MCD: 231 bp, MCP-1: 157 bp, M-CPT-I: 222 bp, PDK-4:
168 bp, PGC-1: 234 bp, p22: 215 bp and APRT: 329 bp).
The results for the expression of specific mRNAs are
always presented relative to the expression of the control
gene (aprt).
1.6. Immunoblotting
Cell lysates and nuclear extracts from H9c2 cells were
obtained as previously described [25]. Proteins (50 Ag) were
separated by SDS–PAGE on 10% separation gels and
transferred to Immobilon polyvinylidene diflouride mem-involved in fatty acid lipid metabolism in PE-stimulated neonatal rat
(C) and PGC-1 (C) in PE-stimulated cardiac myocytes in the presence or
ation normalized to the APRT mRNA levels are shown. Data are expressed
###Pb0.001 vs. PE-stimulated cardiac myocytes.
A. Planavila et al. / Cardiovascular Research 65 (2005) 832–841836branes (Millipore, Bedford, MA). Western blot analysis was
performed using antibodies against InBa, InBh, p65 and
PPARh/y (Santa Cruz Biotechnology) and h-tubulin
(Sigma). Detection was achieved using the EZ-ECL
chemiluminescence detection kit (Biological Industries, Beit
Haemek, Israel). Size of detected proteins was estimated
using protein molecular-mass standards (Life Technologies).
1.7. Electrophoretic mobility shift assay (EMSA)
H9c2 cells were pretreated with 10 Amol/L L-165041 for
24 h before stimulation with LPS (10 ng/ml) for 1 h.
Isolation of nuclear extracts and EMSA were performed as
previously described [25].
1.8. Coimmunoprecipitation
Cell nuclear extracts were brought to a final volume of
0.5 mL with buffer containing 10 mM PBS, 50 mM KCl,
0.05 mM EDTA, 2.5 mM MgCl2, 8.5% glycerol, 1 mM
dithiothreitol, 0.1% Triton X-100, BSA 2% and 1 mg/ml
nonfat milk for 6 h at 4 8C and incubated with 4 Ag of
anti-p65. Immunocomplex were captured by incubating
the samples with protein A-agarose suspension overnight
at 4 8C on a rocker platform. Agarose beads were
collected by centrifugation and washed three times with
PBS containing protease inhibitors. After microcentrifuga-
tion, the pellet was washed with 60 Al of SDS–PAGE
sample buffer and boiled for 5 min at 100 8C. An aliquot
of the supernatant was subjected to electrophoresis on
10% SDS–PAGE and immunoblotted with an antibody
against PPARh/y.
1.9. Statistical analyses
Results were obtained from at least four independent
experiments and presented as meanFS.D. Comparisons
between groups were performed with one-way ANOVA
using the computer program GraphPad Instat (GraphPad
Softwware, San Diego, CA). When significant variations
were found, the Tukey–Kramer multiple comparisons test
was performed. Differences were considered significant at
Pb0.05.Fig. 3. Effects of L-165041 of the expression of NADPH oxidase subunits
and iNOS. Analysis of the mRNA levels of gp91 (A), p22 (B) and iNOS
(C) in PE-stimulated cardiac myocytes in the presence or absence of 10
Amol/L L-165041. A representative autoradiogram is shown. Experiments
were performed three times with similar results.2. Results
2.1. PPARb/d activation by L-165041 inhibits PE-induced
cardiac hypertrophy in neonatal rat cardiomyocytes
Cardiac hypertrophy leads to significant increases in
protein content (e.g., [3H]leucine uptake), induction of fetal-
type genes (e.g., ANF) and cardiac myocyte size [26].
Therefore, we first examined the effects on these parameters
of the specific PPARh/y agonist L-165041, which was
previously shown to be selective for this PPAR-subtype at10 Amol/L [27]. The cells were pretreated with either
vehicle or L-165041 for 30 min and subsequently stimulated
with 100 Amol/L PE for 24 h. As shown in Fig. 1A,
[3H]leucine incorporation was significantly increased by PE
(1.6-fold, Pb0.001) and this was inhibited by L-165041
(20%, Pb0.05). PE-induced cardiomyocyte hypertrophy
also led to approximately twofold induction in the mRNA
levels of the fetal cardiac gene ANF (Fig. 1B). In contrast, in
the presence of L-165041 PE-induced ANF expression was
abolished. Immunostaining of cardiac myocytes for the
sarcomere-associated protein a-actinin and ANF clearly
shown an increase in cardiac myocyte size and ANF protein
expression following PE stimulation (Fig. 1C). These
changes were blocked by the presence of the PPARh/y
agonist L-165041.
2.2. Treatment with the PPARb/d agonist L-165041 prevents
the reduction in the expression of genes involved in lipid
metabolism caused by PE-induced cardiomyocyte
hypertrophy in neonatal rat cardiomyocytes
An important molecular adaptation in cardiac hyper-
trophy is the increase in glucose utilization and decrease in
fatty acid oxidation associated to a downregulation of the
expression of the mRNA levels of genes involved in fatty
acid metabolism [8]. Interestingly, PPARh/y activates the
expression of several PPAR target genes involved in fatty
acid utilization in cardiac myocytes [21], including M-
CPT-I, which determines the flux of mitochondrial h-
oxidation [28], and PDK-4, which suppresses glucose
A. Planavila et al. / Cardiovascular Research 65 (2005) 832–841 837oxidation by its inhibitory effect on the pyruvate dehydro-
genase complex leading to an increase in fatty acid
utilization [29]. Taking into account these data, we next
assessed the effects of PE-induced cardiomyocyte hyper-
trophy on the mRNA levels of these genes in the presence
or in the absence of L-165041. Induction of cardiomyocyte
hypertrophy by PE led to a reduction in the transcript
levels of both M-CPT-I (50%, Pb0.05) and PDK-4 (30%,
Pb0.05). In contrast, in the presence of the PPARh/y
agonist, PE did not reduce the levels of these genes and
even a robust induction (about fourfold, Pb0.001) was
observed compared to control values (Fig. 2A and B). PE
treatment did not affect the mRNA levels of MCD and
PGC-1, two genes involved in lipid metabolism, whereas
coincubation with L-165041 caused a significant increase
in MCD expression (Fig. 2C and D).Fig. 4. L-165041 inhibits the upregulation of MCP-1 caused by PE and LPS stimul
in neonatal rat cardiomyocytes (A) in the presence or absence of 10 Amol/L L-165
(D) in LPS-stimulated H9c2 cells in the presence or absence of 10 Amol/L L-1650
APRT mRNA levels are shown. Data are expressed as meanFS.D. of six differen
PE- or LPS-stimulated cells.2.3. Treatment with L-165041 inhibits the upregulation of
MCP-1 caused by PE-induced cardiomyocyte hypertrophy
in neonatal rat cardiomyocytes
PE-induced cardiomyocyte hypertrophy in neonatal rat
cardiomyocytes is mediated through NF-nB activation via
the generation of reactive oxygen species (ROS) [4].
NADPH oxidase is one of the systems generating ROS
whose expression is increased in cardiac hypertrophy [30].
We therefore evaluated whether PPARh/y activation by L-
165041 affected the expression of the NADPH oxidase
subunits gp91 and p22 (Fig. 3A and B). No changes were
observed in the mRNA levels of these genes in neonatal
rat cardiomyocytes, making unlikely that reduced NADPH
oxidase expression may account for the antihypertrophic
effect of L-165041. Similarly, L-165041 treatment did notation in myocytes. Analysis of the mRNA levels of MCP-1 in PE-stimulated
041. Analysis of the mRNA levels of MCP-1 (B), M-CPT-I (C) and PDK-4
41. A representative autoradiogram and the quantification normalized to the
t experiments. *Pb0.05 and ***Pb0.001 vs. control. ###Pb0.001 vs. either
Fig. 6. Treatment with L-165041 does not affect the protein levels of InBa.
Protein extracts from H9c2 myotubes stimulated with LPS for 1 h in the
presence or the absence of 10 Amol/L L-165041 were assayed for Western
blot analysis with PPARh/y (A), p65 (B), InBa (C) InBh (D) and h-tubulin
(E) antibodies.
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involved in maladaptive consequences of cardiac hyper-
trophy [31] (Fig. 3C). Next, we determined the effects of
L-165041 on the expression of MCP-1, a gene under the
transcriptional control of NF-nB [32], in neonatal rat
cardiomyocytes. Stimulation of cardiac myocytes with PE
enhanced twofold the expression of this gene and this was
abolished by L-165041 (Fig. 4A). This data suggests that
prevention of NF-nB activation may be involved in the
antihypertrophic effect attained by PPARh/y activation.
Because of limited amount of mRNA and proteins
obtained from neonatal rat cardiomyocytes, we continue
our studies in the embryonic rat-heart derived H9c2 cells
to confirm the involvement of NF-nB in the changes
observed after L-165041 treatment. Gilde et al. [21]
recently reported that H9c2 cells abundantly express the
PPARh/y subtype, whereas PPARa and g were undetect-
able. This fact converts H9c2 cells in a proper tool to
investigate the role of PPARh/y activation without the
potential interference of the other PPAR subtypes. In order
to activate NF-nB, H9c2 cells were stimulated for 24 h
with LPS, which has been reported to activate NF-nB in
cardiomyocytes [33]. As expected, a robust induction
(sevenfold, Pb0.001) was observed in the mRNA levels
of the NF-nB target gene MCP-1 (Fig. 4B), that was
significantly reduced (25%, Pb0.001) in the presence of
L-165041. The stimulation of H9c2 cells with LPS also
caused a similar pattern of changes in the expression of
genes involved in fatty acid metabolism to those observed
in PE-induced cardiomyocyte hypertrophy in neonatal rat
cardiomyocytes. Thus, a 20% and a 40% reduction were
observed in the mRNA levels of M-CPT-I and PDK-4,
respectively, and these changes were prevented in the
presence of L-165041 (Fig. 4C and D).
2.4. Treatment with the PPARb/d Activator L-165041
reduces LPS-induced NF-jB activation
Since activation of NF-nB is required for hypertrophic
growth of cardiomyocytes [3–6] and MCP-1 transcriptionFig. 5. Treatment with the PPARh/y activator L-165041 reduces LPS-induced NF
with a 32P-labeled NF-nB nucleotide and crude nuclear protein extract (NE) shows
of unlabeled probe. (B) Autoradiograph of EMSA performed with a 32P-labeled NF
the presence or the absence of 10 Amol/L L-165041. (C) Supershift analysis perfor
NF-kB. Supershifted immune complex (IC) is denoted.is regulated by this transcription factor, we performed
EMSAs to investigate whether the PPARh/y activator
L-165041 inhibited LPS-induced NF-nB activation in
H9c2 cells. EMSA studies shown that the NF-nB probe
formed three complexes with cardiac nuclear proteins
(complexes I to III, Fig. 5). Specificity of the three
DNA-binding complexes was assessed in competition
experiments by adding an excess of unlabeled NF-nB
oligonucleotide to incubation mixtures (Fig. 5A). NF-nB
binding activity, mainly of specific complex II, increased
in cells stimulated with LPS for 1 h (Fig. 5B). In
contrast, in the presence of L-165041 the LPS-induced
increase in NF-nB binding activity was abolished.
Characterization of NF-nB was performed by incubating
nuclear extracts with an antibody directed against the p65
subunit of NF-nB. Addition of this antibody to incuba-
tion mixtures resulted in complete supershift of complex
II, thus showing that this complex contained p65. No
changes were observed in the DNA binding of nuclear
proteins to an Oct-1 probe, indicating that the increase
observed for the NF-nB probe was specific (data not-nB activation in H9c2 myotubes. (A) Autoradiograph of EMSA performed
three specific complexes (I to III), based on competition with a molar excess
-nB nucleotide and NE from H9c2 myotubes stimulated with LPS for 1 h in
med by incubating NE with an antibody directed against the p65 subunit of
Fig. 7. L-165041 enhances PPARh/y association with the p65 subunit of
NF-nB. Nuclear extracts from H9c2 myotubes stimulated with LPS for 1 h
in the presence or the absence of 10 Amol/L L-165041 were subjected to
immunoprecipitation using anti-p65 antibody coupled to protein-A agarose
beads. Immunoprecipitates were subjected to SDS–PAGE and immuno-
blotted with an anti-PPARh/y antibody. The blot data are representative of
three separate experiments.
A. Planavila et al. / Cardiovascular Research 65 (2005) 832–841 839shown). Overall, these data demonstrate that PPARh/y
activation by L-165041 inhibits LPS-induced NF-nB
activation.
2.5. Treatment with the PPARb/d activator enhances its
interaction with the p65 subunit of NF-kB
Finally, we sought to determine the molecular mecha-
nism by which the PPARh/y activator L-165041 inhibits
LPS-induced NF-nB activation. Since it has been proposed
that PPARh/y and PPARa share similar biological roles
[21], we studied whether PPARh/y inhibited NF-nB
signaling through mechanisms similar to those reported
for PPARa. Activation of PPARa may result in inhibition
of NF-nB signaling through different mechanisms. First,
PPARa activators have been reported to induce the
expression of InBa, which forms a cytoplasmic inactive
complex with the p65–p50 heterodimeric complex [34,35].
We did not observe significant changes in the protein
expression of PPARh/y, the p65 subunit of NF-nB, InBa
or InBh after L-165041 treatment (Fig. 6), suggesting that
PPARh/y activation did not act through this mechanism. In
addition, PPARa activators may act through DNA-binding
independent mechanisms that may involve a physical
interaction with NF-nB. This association prevents NF-nB
from binding to its response element and thereby inhibits
its ability to induce gene transcription [16]. In order to
evaluate whether PPARh/y activation acts through a
similar mechanism, we performed coimmunoprecipitation
studies with isolated nuclear extracts using antibodies
against the p65 subunit of NF-nB and PPARh/y. Data
shown in Fig. 7 demonstrate that addition of the PPARh/y
agonist L-165041 strongly enhanced the physical inter-
action between p65 and PPARh/y, suggesting that
increased association between these two proteins is the
mechanism through which PPARh/y activation prevents
NF-nB activation.3. Discussion
In the present study, we demonstrate that activation of
PPARh/y by the specific ligand L-165041 inhibits PE-
induced cardiomyocyte hypertrophy in neonatal rat cardio-
myocytes. Treatment with L-165041 also inhibited PE-
induced expression of the NF-nB-target gene MCP-1,
suggesting that the antihypetrophic effect of this compound
involves downregulation of NF-nB signaling pathway.
Further, it is shown that L-165041 may inhibit LPS-induced
NF-nB activation through enhanced physical interaction of
PPARh/y with the p65 subunit of NF-nB.
Several studies have reported that both PPARa and
PPARg activators inhibit cardiac hypertrophy [36–39]. In
contrast, the biologic role of PPARh/y activation in cardiac
hypertrophy was unknown. The availability of selective
PPARh/y ligands, such as L-165041, opened the possibility
of studying the role of this PPAR subtype in cardiac cells.
Thus, previous data of a recent study [21] pointed to an
important function of PPARh/y in the heart. The authors
demonstrated that both PPARa and PPARh/y were
expressed in comparable levels in heart, whereas PPARg
was barely detectable. Further, PPARh/y was fatty acid
inducible and activated the expression of PPARa target
genes involved in fatty acid utilization in cardiac myocytes.
The authors of this study suggested that PPARa and
PPARh/y shared similar functions in cardiac cells regarding
cardiac fatty acid metabolism. In agreement with this idea,
Muoio et al. [40] shown that fatty acid oxidation in skeletal
muscle of PPARa/ mice was not impaired, probably
because of PPARh/y compensated for the lack of PPARa in
these mice. In the present study, we define a new role for
PPARh/y activation, inhibition of cardiomyocyte hyper-
trophy. Therefore, given the abundant expression of both
PPARa and PPARh/y in heart and the fact that PPARa
activation also inhibits cardiac hypertrophy [41,42], these
PPAR subtypes may also share similar roles in the
development of cardiac hypertrophy.
It is still a matter of controversy whether changes in
intracellular substrate and metabolite levels in cardiomyo-
cytes are the consequence or the reason for cardiac
hypertrophy. However, several factors support a role for
cardiac metabolism in the development of cardiac hyper-
trophy. Thus, an increase in the activities of several
glycolytic enzymes has been reported prior to cardiac
hypertrophy [7]. Moreover, the fact that PPARa gene
influences human left ventricular growth in response to
exercise and hypertension, indicates that maladaptative
cardiac substrate utilization can play a causative role in
the pathogenesis of left ventricular hypertrophy [43]. In the
present work, stimulation of rat neonatal cardiomyocytes
with PE, which leads to NF-nB activation [4], caused
cardiomyocyte hypertrophy that was accompanied by a fall
in the expression of genes involved in fatty acid metabo-
lism, such as M-CPT-I and PDK-4. This effect was
abolished by the addition of the PPARh/y activator
A. Planavila et al. / Cardiovascular Research 65 (2005) 832–841840L-165041, which strongly induced the expression of these
genes. Further studies are necessary to clearly establish
whether pharmacological modulation of cardiac fatty acid
metabolism with either PPARa or PPARh/y activators is
enough to alleviate or inhibit cardiac hypertrophy. However,
it is worth noting that treatment of H9c2 cells with LPS for
24 h caused a similar pattern of changes in the expression of
M-CPT-I and PDK-4 to those observed in PE-induced
cardiomyocyte hypertrophy. Since both PE-induced cardi-
omyocyte hypertrophy and LPS lead to NF-nB activation,
these data point to the involvement of this transcription
factor in the downregulation of genes involved in fatty acid
metabolism. Activation of PPARh/y would inhibit NF-nB
signaling pathway avoiding both cardiomyocyte hyper-
trophy and downregulation of genes involved in fatty acid
metabolism. Furthermore, and although, it is not the
objective of this study, apoptosis is considered an important
factor in the progression from cardiac hypertrophy to heart
failure. Activation of NF-nB is involved in direct regulation
of both anti- and proapoptotic effects [44] and the latter
maybe stimulated by LPS.
Interestingly, L-165041 reduced the induction of the
NF-nB target gene MCP-1 in cardiac cells stimulated by
either PE or LPS, suggesting that PPARh/y may antag-
onize NF-nB activation. Enhanced myocardial MCP-1 has
been described in the hypertrophied and failing heart [45]
and may lead to the infiltration and activation of
inflammatory cells, such as monocytes/macrophages and
lymphocytes. In addition, it has been reported that
activation of MCP-1 expression contributes to left
ventricular remodeling and failure after myocardial infarc-
tion [46]. Therefore, PPARh/y activation may become a
therapeutic option to reduce the expression of MCP-1 in
heart. It is important to note that the inhibitory effect of
L-165041 on LPS-induced MCP-1 expression was of
lower intensity that the observed for PE. This probably
reflects the higher induction achieved by LPS stimulation
(sevenfold induction) compared to PE (twofold induction)
and/or differences in the two cell system used. The use of
H9c2 myotubes, which only express PPARh/y, offers the
advantage of avoiding the interference of other PPAR
subtypes and, therefore, permits to adscribe the changes
observed to this transcription factor. However, LPS-treat-
ment of H9c2 myotubes was performed to achieve NF-nB
activation, but not cardiac hypertrophy, and consequently
the findings observed in these cells should be limited to
the activation of NF-nB by LPS.
PPARa activators may inhibit NF-nB signaling through
different mechanisms [16,47,48]. One of these mechanisms
involves physical interaction of PPARa and the p65
subunit of NF-nB [16]. Here, we demonstrate that
PPARh/y activation by L-165041 enhances the protein-
protein association between PPARh/y and p65, indicating
that this mechanism may interfere NF-nB transactivation
capacity. Therefore, PPARa and PPARh/y may also share
similar mechanisms of action inhibiting NF-nB signaling.Further studies are necessary to investigate whether
PPARh/y activation may inhibit the NF-nB signaling
pathway through additional mechanisms or affects the
activity of other transcription factors involved in cardiac
hypertrophy, such as nuclear factor of activated T
lymphocyte (NFAT).
In summary, in the present study, we show that PPARh/y
activation inhibits PE-induced cardiomyocyte hypertrophy
in neonatal rat ventricular cardiomyocytes. PPARh/y acti-
vation also inhibits LPS-induced NF-nB activation through
a mechanism that may involve enhanced protein–protein
interaction between this PPAR subtype and the p65 subunit
of NF-nB. These data indicate that inhibition of the NF-nB
signaling pathway may be the underlying mechanism
responsible for the inhibition of cardiomyocyte growth.Acknowledgments
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